141 related articles for article (PubMed ID: 10959506)
1. Nomograms used to define the short-term treatment with PGE(1) in patients with intermittent claudication and critical ischemia. The ORACL.E (Occlusion Revascularization in the Atherosclerotic Critical Limb) Study Group. The European Study.
Belcaro G; Nicolaides AN; Cipollone G; Laurora G; Incandela L; Cazaubon M; Barsotti A; Ledda A; Errichi BM; Cornelli U; Dugall M; Corsi M; Mezzanotte L; Geroulakos G; Fisher C; Szendro G; Simeone E; Cesarone MR; Bucci M; Agus G; De Sanctis MT; Ricci A; Ippolito E; Vasdekis S; Christopoulos D; Helmis H
Angiology; 2000 Aug; 51(8 Pt 2):S3-13; discussion S14. PubMed ID: 10959506
[TBL] [Abstract][Full Text] [Related]
2. PGE(1) treatment of severe intermittent claudication (short-term versus long-term, associated with exercise)--efficacy and costs in a 20-week, randomized trial.
Belcaro G; Nicolaides AN; Agus G; Cesarone MR; Geroulakos G; Pellegrini L; De Sanctis MT; Incandela L; Ricci A; Mondani P; De Angelis R; Ippolito E; Barsotti A; Vasdekis S; Ledda A; Christopoulos D; Errichi BM; Helmis H; Cornelli U; Ramaswami G; Dugall M; Bucci M; Martines G; Ferrari PG; Corsi M; Di Francescantonio D
Angiology; 2000 Aug; 51(8 Pt 2):S15-26. PubMed ID: 10959507
[TBL] [Abstract][Full Text] [Related]
3. Treatment of severe intermittent claudication with PGE1--a short-term vs a long-term infusion plan--a 20 week, European randomized trial--analysis of efficacy and costs.
Belcaro G; Laurora G; Nicolaides AN; Agus G; Cesarone MR; DeSanctis MT; Incandela L; Ricci A; Cazaubon M; Ippolito E; Barsotti A; Vasdekis S; Ledda A; Iacobitti P; Christopoulos D; Errichi BM; Helmis H; Cornelli U; Ramaswami G; Bucci M; Ferrari PG; Corsi M; Pomante P; Mezzanotte L; Geroulakos G
Angiology; 1998 Nov; 49(11):885-94; discussion 895. PubMed ID: 9822044
[TBL] [Abstract][Full Text] [Related]
4. [Severe intermittent claudication: PGE1 treatment. A 40-week registry, efficacy and costs].
Luzzi R; Belcaro G; Ippolito E; Dugall M; Cesarone MR; Scoccianti M; Errichi BM; Pellegrini L; Ciammaichella G; Ledda A; Ricci A; Cornelli U; Feragalli B; Hosoi M; Corsi M; Simeone E; Agus GB
Minerva Cardioangiol; 2012 Aug; 60(4):405-13. PubMed ID: 22858918
[TBL] [Abstract][Full Text] [Related]
5. [European trial of PGE1 alpha cyclodextrin. Short-term vs. long-term therapy in intermittent claudication].
Laurora G; Corsi M; Bucci M; Cesarone MR; Belcaro G; Dugall M
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):21-9. PubMed ID: 10658441
[TBL] [Abstract][Full Text] [Related]
6. Impact of a 4-week treatment with prostaglandin E1 on health-related quality of life of patients with intermittent claudication.
Mangiafico RA; Messina R; Attinà T; Dell'Arte S; Giuliano L; Malatino LS
Angiology; 2000 Jun; 51(6):441-9. PubMed ID: 10870853
[TBL] [Abstract][Full Text] [Related]
7. [Global analysis of data from studies with PDE1 alpha-cyslodextrin].
Laurora G; Belcaro G; Cesarone MR; Incandela L; De Sanctis MT; Dugall M
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):65-8. PubMed ID: 10658448
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of severe intermittent claudication: ORACLE-PGE1 short term study. A randomised 40-week study. Evaluation of efficacy and costs].
Cesarone MR; Belcaro G; Nicolaides AN; Griffin M; Geroulakos G; Ramaswami G; Cazaubon M; Barsotti A; Vasdekis S; Christopoulos D; Agus G; Bavera P; Mondani P; Ippolito E; Flenda F
Minerva Cardioangiol; 2002 Dec; 50(6):683-90. PubMed ID: 12473989
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of costs and results of prostaglandin (PGE1 alpha-cyclodestrin) therapy of peripheral arterial diseases].
Bucci M; Iacobitti P; Laurora G; Cesarone MR
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):9-15. PubMed ID: 10658439
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1.
Milio G; Novo G; Genova C; Luigi Almasio P; Novo S; Pinto A
Cardiovasc Drugs Ther; 2009 Aug; 23(4):301-6. PubMed ID: 19548076
[TBL] [Abstract][Full Text] [Related]
11. [Reduction of cardiovascular morbidity/mortality in arteriopathies treated ith PGE1 alpha-cyclodextrin].
Belcaro G; Bucci M; Cesarone MR; Incandela L; De Sanctis MT
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):51-4. PubMed ID: 10658445
[TBL] [Abstract][Full Text] [Related]
12. [Intramuscular injections of PGE1 in patients with severe claudication].
Corsi M; Laurora G; Cesarone MR
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):59-63. PubMed ID: 10658447
[TBL] [Abstract][Full Text] [Related]
13. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.
Böger RH; Bode-Böger SM; Thiele W; Creutzig A; Alexander K; Frölich JC
J Am Coll Cardiol; 1998 Nov; 32(5):1336-44. PubMed ID: 9809945
[TBL] [Abstract][Full Text] [Related]
14. Effects of intravenous lipoprostaglandin E1 on neurogenic intermittent claudication.
Murakami M; Takahashi K; Sekikawa T; Yasuhara K; Yamagata M; Moriya H
J Spinal Disord; 1997 Dec; 10(6):499-504. PubMed ID: 9438815
[TBL] [Abstract][Full Text] [Related]
15. ["Responders and non-responders" to PGE1 and alpha-cyclodextrin].
De Sanctis MT; Incandela L; Iacobitti P
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):31-6. PubMed ID: 10658442
[TBL] [Abstract][Full Text] [Related]
16. [Cardiovascular morbidity/mortality modified by the use of FGE1 alpha-cyclodextran and calcium heparin in patients with severe vascular diseases].
Belcaro G; Cesarone MR; Bucci M; Iacobitti P; Dugall M
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):55-8. PubMed ID: 10658446
[TBL] [Abstract][Full Text] [Related]
17. [Increasing transcutaneous PO2 in arteriopathies during treatment with PGE1 alpha-cyclodextrin].
Belcaro G; Cesarone MR
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):37-43. PubMed ID: 10658443
[TBL] [Abstract][Full Text] [Related]
18. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia.
Brass EP; Anthony R; Dormandy J; Hiatt WR; Jiao J; Nakanishi A; McNamara T; Nehler M;
J Vasc Surg; 2006 Apr; 43(4):752-9. PubMed ID: 16616232
[TBL] [Abstract][Full Text] [Related]
19. Effect of High-pressure, Intermittent Pneumatic Compression for the Treatment of Peripheral Arterial Disease and Critical Limb Ischemia in Patients Without a Surgical Option.
Alvarez OM; Wendelken ME; Markowitz L; Comfort C
Wounds; 2015 Nov; 27(11):293-301. PubMed ID: 26574751
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: results of a multicenter placebo-controlled double-blind trial.
Diehm C; Balzer K; Bisler H; Bulling B; Camci M; Creutzig A; Gruss JD; Horsch S; Odemar F; Piehler U; Rogatti W; Scheffler P; Spengel F; Treese N; Turowski A; Waldhausen P; Weber B; Weiss T
J Vasc Surg; 1997 Mar; 25(3):537-44. PubMed ID: 9081136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
